Editorial
doi: 10.1001/jamapediatrics.2019.4509.
Omalizumab for Atopic Dermatitis: Overtreatment or Lifesaver?
Affiliations
- PMID: 31764954
- DOI: 10.1001/jamapediatrics.2019.4509
Item in Clipboard
Editorial
Omalizumab for Atopic Dermatitis: Overtreatment or Lifesaver?
JAMA Pediatr.
.
No abstract available
Comment on
-
Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial.JAMA Pediatr. 2020 Jan 1;174(1):29-37. doi: 10.1001/jamapediatrics.2019.4476. JAMA Pediatr. 2020. PMID: 31764962 Free PMC article. Clinical Trial.
Similar articles
-
Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT): the role of anti-IgE in severe paediatric eczema: study protocol for a randomised controlled trial.Trials. 2017 Mar 22;18(1):136. doi: 10.1186/s13063-017-1809-7. Trials. 2017. PMID: 28330497 Free PMC article. Clinical Trial.
-
[Omalizumab as a therapeutic option in atopic eczema. Current evidence and potential benefit].Hautarzt. 2007 Feb;58(2):128, 130-2. doi: 10.1007/s00105-006-1280-y. Hautarzt. 2007. PMID: 17237929 German.
-
Omalizumab for treatment of refractory severe atopic dermatitis. A pediatric perspective.Dermatol Ther. 2020 Jul;33(4):e13519. doi: 10.1111/dth.13519. Epub 2020 May 22. Dermatol Ther. 2020. PMID: 32378300
-
Lack of omalizumab efficacy in severe atopic dermatitis with extremely elevated IgE levels: two case reports and a literature review.Acta Dermatovenerol Alp Pannonica Adriat. 2019 Jun;28(2):89-92. Acta Dermatovenerol Alp Pannonica Adriat. 2019. PMID: 31233174 Review.
-
Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis.J Allergy Clin Immunol. 2016 Dec;138(6):1719-1722.e1. doi: 10.1016/j.jaci.2016.05.038. Epub 2016 Jul 14. J Allergy Clin Immunol. 2016. PMID: 27543070 Review. No abstract available.
Cited by
-
Treatment-resistant atopic dermatitis: novel therapeutics, digital tools, and precision medicine.Asia Pac Allergy. 2022 Apr 28;12(2):e20. doi: 10.5415/apallergy.2022.12.e20. eCollection 2022 Apr. Asia Pac Allergy. 2022. PMID: 35571547 Free PMC article. Review.
-
Pediatric usage of Omalizumab: A promising one.World Allergy Organ J. 2021 Dec 11;14(12):100614. doi: 10.1016/j.waojou.2021.100614. eCollection 2021 Dec. World Allergy Organ J. 2021. PMID: 34963793 Free PMC article. Review.
-
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.Clin Exp Allergy. 2021 Jul;51(7):915-931. doi: 10.1111/cea.13954. Epub 2021 Jun 26. Clin Exp Allergy. 2021. PMID: 34037993 Free PMC article.
